There is a paucity of information regarding antimicrobial agents that are suitable to treat severe infections caused by multidrug-resistant Campylobacter spp. Our aim was to identify agents that are potentially effective against multiresistant Campylobacter strains. The in vitro activities of 20 antimicrobial agents against 238 Campylobacter strains were analyzed by determining MICs by the agar plate dilution method or the Etest. These strains were selected from 1,808 Campylobacter isolates collected from Finnish patients between 2003 and 2005 and screened for macrolide susceptibility by using the disk diffusion test. The 238 strains consisted of 183 strains with erythromycin inhibition zone diameters of <23 mm and 55 strains with inhibition zone diameters of >23 mm. Of the 238 Campylobacter strains, 19 were resistant to erythromycin by MIC determinations (MIC > 16 g/ml). Given that the resistant strains were identified among the collection of 1,808 isolates, the frequency of erythromycin resistance was 1.1%. All erythromycin-resistant strains were multidrug resistant, with 18 (94.7%) of them being resistant to ciprofloxacin (MIC > 4 g/ml). The percentages of resistance to tetracycline and amoxicillin-clavulanic acid (coamoxiclav) were 73.7% and 31.6%, respectively. All macrolide-resistant strains were susceptible to imipenem, meropenem, and tigecycline. Ten (52.6%) multiresistant strains were identified as being Campylobacter jejuni strains, and 9 (47.4%) were identified as being C. coli strains. These data demonstrate that the incidence of macrolide resistance was low but that the macrolide-resistant Campylobacter strains were uniformly multidrug resistant. In addition to the carbapenems, tigecycline was also highly effective against these multidrug-resistant Campylobacter strains in vitro. Its efficacy for the treatment of human campylobacteriosis should be evaluated in clinical trials.
Campylobacteriosis is usually a mild and self-limiting disease requiring no antimicrobial treatment (3, 5) . Only rarely is it associated with extraintestinal manifestations, e.g., septicemia, skin and soft tissue infection, infective endocarditis, or meningitis (3) . These infections usually require treatment with intravenous antimicrobial agents (3) . Infections of immunocompromised patients and pregnant women as well as very young and very old patients or those with persisting symptoms (Ͼ1 week) also require antimicrobial treatment (3) . Guillain-Barré syndrome and reactive arthritis are major postinfectious complications of campylobacteriosis (3, 24, 26) .
For many years, macrolides and fluoroquinolones have been the first-and second-choice alternatives for the antimicrobial treatment of campylobacter enteritis. Since the late 1980s, however, the emergence of resistance to these antimicrobial groups has complicated the treatment of this disease (1) . For example, in Thailand, the rate of resistance to the fluoroquinolones has been up to 80% (8, 14) . In Finland, the rate of fluoroquinolone resistance increased between 1995 and 2000 from 40% to 60% among all travelers' isolates and from 45% to 72% among those from Asia alone (11) . So far, resistance to macrolides has remained at quite a low level and stable. According to our previous study (12) , the frequency of macrolide resistance was 2% among 376 Campylobacter jejuni strains collected from Finnish patients during 1995 to 2000. However, there have been a few studies showing that in some countries, the rate of macrolide resistance may be slowly increasing (28) . The emergence of macrolide resistance is of serious concern since macrolide-resistant strains are usually resistant to fluoroquinolones and other antimicrobial groups (12, 14) . Very few alternatives with which to treat campylobacteriosis caused by these multidrug-resistant strains exist. Also, previous studies have shown that patients infected with a quinolone-or erythromycin-resistant Campylobacter strain have an increased risk of an adverse event compared with patients infected with a quinolone-and erythromycin-susceptible Campylobacter strain (9, 13, 27) .
The aim of this study was to identify antimicrobial agents that, based on in vitro activities, could be useful against infections caused by multidrug-resistant Campylobacter strains. 
RESULTS

Strain collection. Of the 1,808
Campylobacter isolates, all 202 isolates exhibiting inhibition zone diameters of Յ23 mm in erythromycin screenings were included in this study. In addition, we randomly selected 60 isolates exhibiting erythromycin zone diameters of Ͼ23 mm to serve as erythromycin-susceptible control strains. From those 262 isolates, 24 did not grow after freezing and storage. Thus, our strain collection consisted of 238 Campylobacter strains, 183 of which exhibited erythromycin inhibition zone diameters of Յ23 mm and 55 of which exhibited zone diameters of Ͼ23 mm. Of these strains, 122 were of foreign origin and 92 were of domestic origin. The origin was unknown for 24 strains. There were 220 (92.4%) strains identified as being C. jejuni strains and 18 (7.6%) strains identified as being C. coli strains. Only four (22.2%) C. coli strains were domestic, while 88 (40%) C. jejuni strains were domestic.
Erythromycin susceptibility. Of the 183 Campylobacter strains with inhibition zone diameters of Յ23 mm in the erythromycin disk screening, 19 were classified by the agar plate dilution method as being erythromycin resistant (MIC Ն 16 g/ml) and 164 were classified as being erythromycin susceptible (MIC Ͻ 16 g/ml). All of the 55 strains with inhibition zone diameters of Ͼ23 mm were classified by the agar plate dilution method as being erythromycin susceptible. Thus, the final study collection consisted of 219 erythromycin-susceptible and 19 erythromycin-resistant Campylobacter strains. Given that the 19 erythromycin-resistant strains were identified among the initial study collection of 1,808 isolates, it can be estimated that the frequency of erythromycin resistance in Campylobacter spp. was 1.1%. To confirm the adequacy of our screening approach, the results of the erythromycin disk screening were compared with the erythromycin MICs. All 19 strains classified as being erythromycin resistant based on MIC determinations had erythromycin inhibition zone diameters of Յ20 mm, while all strains exhibiting zone diameters of Ն21 mm were classified by MIC determination as being erythromycin susceptible.
Among the erythromycin-resistant strains, 17 (89.5%) were foreign, one was domestic, and for one strain, the origin was unknown. Ten (52.6%) resistant strains were identified as being C. jejuni isolates, and nine (47.4%) strains were identified as being C. coli strains. Erythromycin resistance was significantly more common among C. coli than among C. jejuni strains (P Ͻ 0.001). Compared to the C. jejuni strains, the C. coli strains were also significantly more commonly resistant to several other antimicrobial agents ( Table 1) .
Susceptibility of the macrolide-resistant and -susceptible strains to other antimicrobials. The susceptibilities of the erythromycin-resistant and -susceptible Campylobacter strains to 19 additional antimicrobial agents were different ( Table 2) . As determined by the agar plate dilution method, the MIC 50 and MIC 90 of erythromycin for the 19 erythromycin-resistant strains were Ͼ128 g/ml. The MIC 50 s and MIC 90 s were 32 and Ͼ128 g/ml for telithromycin and 64 and 64 g/ml for clindamycin, respectively, with these being lower than those for azithromycin and clarithromycin. The respective MIC 50 s and MIC 90 s were 16 and Ͼ32 g/ml for ciprofloxacin, 4 and 64 g/ml for co-amoxiclav, and 8 and 128 g/ml for ampicillin. VOL. 54, 2010 SUSCEPTIBILITIES OF MULTIRESISTANT CAMPYLOBACTER SPP.
Imipenem, meropenem, gentamicin, and sitafloxacin exhibited the lowest MIC 50 s and MIC 90 s. As determined by the Etest, the MIC 50 s and MIC 90 s of tigecycline were 0.008 and 0.023 g/ml for the erythromycin-resistant strains and 0.008 and 0.032 g/ml for the erythromycin-susceptible strains, respectively. Compared to the erythromycin-susceptible Campylobacter strains, the erythromycin-resistant strains were significantly more commonly resistant to several antimicrobial agents presented in Table 2 .
Of the 19 erythromycin-resistant strains, 17 (89.5%) were highly resistant (MIC Ն 128 g/ml) and also resistant to azithromycin (MIC Ն 4 g/ml) and clindamycin (MIC Ն 8 g/ml). Eighteen (94.7%) strains had telithromycin MICs of Ն8 g/ml, including 14 strains with MICs of Ͼ32 g/ml. All 19 erythromycin-resistant strains were multidrug resistant, with 18 (94.7%) of them being resistant to ciprofloxacin (MIC Ն 4 g/ml). Six strains had MICs of co-amoxiclav of between 32 and 64 g/ml, and seven strains had MICs of ampicillin of between 32 and Ͼ128 g/ml. There were 14 (73.7%) strains that were resistant to tetracycline (MIC Ն 16 g/ml).
Of all 238 Campylobacter strains, 107 (45.0%) were ciprofloxacin resistant; of them, 35 (32.7%) were multidrug resistant. The proportion of tetracycline resistance was 30.7% (73/ 238) in the whole study population.
DISCUSSION
In the present study, the macrolide-resistant Campylobacter strains were uniformly multidrug resistant. There is a paucity of information regarding antimicrobial agents that could be used for serious infections if caused by these multidrug-resis- b Resistance breakpoints according to the CLSI were as follows: ciprofloxacin, Ն4 g/ml; norfloxacin, Ն16 g/ml; ofloxacin, Ն8 g/ml; levofloxacin, Ն8 g/ml; imipenem, 16 g/ml; meropenem, Ն16 g/ml; tetracycline, Ն16 g/ml; gentamicin, Ն16 g/ml; and chloramphenicol, Ն32 g/ml. Resistance breakpoints according to our previous work were as follows: erythromycin, Ն16 g/ml; azithromycin, Ն4 g/ml; clindamycin, Ն 8 g/ml; nalidixic acid, Ն32 g/ml; ampicillin, Ն32 g/m; and co-amoxiclav, Ն32 g/ml. The resistance breakpoint for tigecycline according to EUCAST was Ͼ0.5 g/ml. b Resistance breakpoints according to the CLSI were as follows: ciprofloxacin, Ն4 g/ml; norfloxacin, Ն16 g/ml; ofloxacin, Ն8 g/ml; levofloxacin, Ն8 g/ml; imipenem, Ն16 g/ml; meropenem, Ն16 g/ml; tetracycline, Ն16 g/ml; gentamicin, Ն16 g/ml; and chloramphenicol, Ն32 g/ml. Resistance breakpoints according to our previous work were as follows: erythromycin, Ն16 g/ml; azithromycin, Ն4 g/ml; clindamycin, Ն8 g/ml; nalidixic acid, Ն32 g/ml; ampicillin, Ն32 g/ml; and co-amoxiclav, Ն32 g/ml. The resistance breakpoint for tigecycline according to EUCAST was Ͼ0.5 g/ml.
c Erythromycin resistance was defined as an MIC of Ն16 g/ml.
tant Campylobacter strains. Since extraintestinal manifestations are uncommon in campylobacteriosis, data on their antimicrobial therapy are based only on anecdotal case reports (4, 18, 21) and small retrospective case series (15, 16) . Thus, the most appropriate protocols for antimicrobial treatment for bacteremic infections, whether caused by susceptible or resistant strains, have not been established. Successful outcomes have been reported previously, especially with the carbapenems (4, 15, 16, 18) . In previous studies, this antimicrobial group has also shown excellent in vitro activities against Campylobacter spp. (12, 25) . Correspondingly, in the present study, all macrolide-resistant strains were susceptible to meropenem and imipenem. Among the older antimicrobial agents, gentamicin was effective, but it is not suitable for use, e.g., for meningitis or during pregnancy. However, gentamicin may be effective against septicemia and other systemic infections in conjunction with carbapenem antibiotics. It is of note that here, tigecycline was also highly active against all Campylobacter strains, including the macrolide-and multidrug-resistant strains. We consider this an important finding due to the limited number of other agents that are potentially effective for the treatment of multidrug-resistant campylobacteriosis.
In campylobacter enteritis, antimicrobial treatment is required at least for immunocompromised patients and during pregnancy (3). The treatment is also required if the patient has severe or persisting symptoms and in cases of bloody diarrhea (3). In enteric infections, the administration of antimicrobials by the peroral route is usually preferable to the intravenous route. Based on the results of the present study, no currently available peroral antimicrobial agent reliably covers the macrolide-resistant Campylobacter strains. All but one erythromycin-resistant strain were resistant to ciprofloxacin here, with the majority of them also being resistant to telithromycin and tetracycline. Co-amoxiclav may offer the best alternative, with only one-third of our strains being resistant. Among the fluoroquinolones, sitafloxacin exhibited low MICs against the macrolide-resistant isolates, and these results were consistent with our previous findings (17) . However, sitafloxacin is not presently on that market and is thus of no clinical consequence. In addition, all macrolide-resistant strains were susceptible to chloramphenicol, which is no longer available in Finland for systemic use.
The present study provides information on the frequency of macrolide resistance in campylobacters in Finland between 2003 and 2005. The finding that 19 of the 1,808 Campylobacter isolates initially included proved to be erythromycin resistant by MIC determinations indicates that the frequency of macrolide resistance was 1.1%. We trust this material to be representative of the macrolide resistance situation in our country during that period, as these isolates comprised about one-fifth of all campylobacters recovered from Finnish patients throughout the study. We also trust that our screening approach was appropriate to identify at least a great majority, if not all, of the macrolide-resistant strains present in the initial study population. The adequacy of the methodology was verified by comparing the results of the screening tests to the results of MIC determinations, with a finding that all isolates with inhibition zone diameters of Ն21 mm were determined by MICs to be susceptible.
Among the 238 strains undergoing species determination, 7.6% were identified as being C. coli strains, and yet almost half (47.4%) of the macrolide-resistant strains were identified as being C. coli strains. This finding is consistent with data from previous studies showing that the C. coli strains are macrolide resistant more often than C. jejuni strains (8, 23) . Because of the increasing trend of resistance among Campylobacter spp., routine susceptibility testing is an important tool to choose an appropriate antimicrobial treatment for the patient. Also, species identification may have therapeutic implications. The in vitro activity of tigecycline against the Campylobacter spp. has been analyzed in one previous study (22) , in which it exhibited the lowest MICs against resistant Campylobacter strains. Clinically, the drug has shown excellent activity, e.g., for the treatment of complicated skin and soft tissue infections (6) , which is known to be one manifestation of extraintestinal campylobacteriosis (15, 18) . Tigecycline circulates primarily as unchanged drug, and its major route of elimination is through the feces, likely via biliary excretion (2, 19) . On this basis, it seems reasonable to assume that tigecycline might be effective even for patients with gastroenteritis.
In conclusion, the incidence of macrolide resistance among Campylobacter spp. was low, but the macrolide-resistant strains were uniformly multidrug resistant. C. coli was significantly more frequently macrolide resistant than C. jejuni. Thus, rapid species identification may have therapeutic implications. Based on our results, no perorally administered antimicrobial agent reliably covers the macrolide-resistant Campylobacter strains.
Co-amoxiclav appears to offer the best treatment alternative, with only one-third of our isolates being resistant. In addition to imipenem and meropenem, tigecycline was also highly effective in vitro against multidrug-resistant Campylobacter strains. The efficacy of tigecycline for the treatment of human campylobacteriosis should be evaluated in clinical trials.
